Navigation Links
First Duplex Test for Parvovirus B19 and Hepatitis A Virus Increases Safety of Human Plasma and Plasma Products
Date:10/4/2010

clotting factors, which have many therapeutic uses. These include treatment of chronic and hereditary diseases and disorders such as hemophilia and primary immunodeficiency diseases. Plasma is also used to treat patients who have suffered severe burns or trauma, and during major surgery.

The presence of B19V DNA in plasma pools as well as plasma products has been reported to be associated with the transmission of B19V by administration of plasma products, especially coagulation factors. There have also been reports on the transmission of HAV through blood and plasma products. Both B19V and HAV are not easily inactivated by traditional methods and so detection by NAT is an important step in ensuring the safety of blood and plasma products.

About Roche Blood Screening Roche is a leader in the global NAT blood screening and plasma market, which is estimated at almost 900 million CHF. Nucleic acid-based tests enable earlier detection of active viral infections than conventional antibody or antigen assays. Roche's real-time PCR-based nucleic acid assays have been used since 1998 to screen blood and plasma products. Currently, more than 225 blood banks worldwide use Roche's automated cobas s 201 system.

About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion
'/>"/>

SOURCE Roche
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. IGEN AMENDS DISTRIBUTION AGREEMENT AND ANNOUNCES FIRST SPECTRUM BUILD-OUT
2. Crescendo Biologics Announces First Triple Knockout Mouse
3. PAREXEL Announces Date of First Quarter Fiscal Year 2011 Earnings Release and Conference Call
4. Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus
5. China-Biotics Hosted its First Investor Day Event
6. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
7. China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results
8. SpectraSan 24 Holds First Public Health and Safety Symposium in Ohio
9. Health Robotics Releases Results of First 20 i.v.STATIONs Return On Investment (ROI) Studies in the USA and Canada
10. Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial
11. Enerkem Announces Construction Start of Worlds First Municipal Waste-to-Biofuels Facility in Edmonton, Alberta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... BEIJING , July 24, 2015 Origin Agritech ... supplier of crop seeds in China , ... third quarter fiscal year 2015 ended June 30, 2015, before ... The Company will host a teleconference on August 5th, 2015, ... time to discuss the results. To participate in ...
(Date:7/24/2015)... 2015 , Adds integrated small ... product offering for chronic kidney disease and oncology patients ... complications and dermatology , Increases group revenue and ... ,the Company"), a leading China -based ... biopharmaceutical products, today announced that it has acquired the ...
(Date:7/23/2015)... LOS ANGELES , July 23, 2015 ImmunoCellular ... plans to report financial results for the second quarter 2015 ... hold a conference call and webcast on that day at ... results and provide a business update. The call will be ...   , , , LIVE CALL: ...
(Date:7/23/2015)... , ... July 23, 2015 , ... Science and technology ... to new drug therapies and devices – according to Susan Chang, MD, director of ... session on how science and new technology are impacting the development of new treatments ...
Breaking Biology Technology:Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 33SBio Acquires Zhejiang Wansheng Pharmaceutical 23SBio Acquires Zhejiang Wansheng Pharmaceutical 33SBio Acquires Zhejiang Wansheng Pharmaceutical 4ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015 2Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 2Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 3
... March 16 The Gynecologic Cancer Foundation (GCF) and the Claudia Cohen Research Foundation ... of the $50,000 GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher.  The prize ... Cancer, meeting in San Francisco March 14-17, 2010 . , ... ...
... March 16 Cylex™, a global life science company that develops and manufactures in vitro diagnostic products based on patented technology, announced today ... "Jim" Brosius. , ... , , ... ...
... ... ... ... VANCOUVER , March 16 /PRNewswire/ - Kinexus Bioinformatics Corporation, a world leader in functional proteomics research, announced the launch ...
Cached Biology Technology:Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 2Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 3Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 4Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 5Cylex Announces Valuable Personnel Additions 2Cylex Announces Valuable Personnel Additions 3Cylex Announces Valuable Personnel Additions 4Cylex Announces Valuable Personnel Additions 5Kinexus Announces the Launch of New Peptide Production Services 2
(Date:7/7/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... announces a revised version of one of its first 30 second ... CNBC in New York , Chicago ... San Francisco metro areas.    , , ... replace all the cards in your wallet and keep your identity ...
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2
... Ariz. and ROSEMONT, Ill. September 12, 2013 ... today announced that the Pac-12,s Arizona State University and ... first university research partner in a new study designed ... groundbreaking joint research project is the first of its ...
... softballs, both approved for league play, can have dramatically different ... findings from a study conducted by Professor Lloyd Smith in ... Derek Nevins that they will present at the Asia Pacific ... Their work was published in the journal, Procedia Engineering ...
... Sept. 12, 2013 Taking a page from ... Research Institute (TGen) today initiated the first-in-human clinical trial ... a plant known as "Thunder God vine." ... received treatment today at Scottsdale Healthcare,s Virginia G. Piper ...
Cached Biology News:ASU football program is first collegiate partner in TGen-Riddell concussion detection study 2ASU football program is first collegiate partner in TGen-Riddell concussion detection study 3ASU football program is first collegiate partner in TGen-Riddell concussion detection study 4Researchers hit virtual heads to make safer games 2TGen and Scottsdale Healthcare launch Phase I 'Thunder God vine' trial for cancer 2TGen and Scottsdale Healthcare launch Phase I 'Thunder God vine' trial for cancer 3
... Versatile state of the Art GLP ... to dual 38,000 L fermentation. ... to production. Aseptic operation capable ... Fed-Batch, and Continuous Modes. Hosts ...
ExonBio Service provides one-stop recobinant protein shopping from cloning, expression and purification. Price including gene cloning....
TRBP1 Antibody...
Request Info...
Biology Products: